NCT06421701View on ClinicalTrials.gov

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

May 31, 2026

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

anti-CD19 CAR-NK cells

Patients will receive Fludarabine and Cyclophosphamide for lymphodepletion conditioning. Anti-CD19 CAR-NK cells will be infused on Day 0, 3, and 6.

Trial Locations (1)

310016

RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER